GlassScriptPhysician profile
George M Gachuma
NPI 1114425832
$1,141.83
in general payments reported to CMS, 2019-2025
9 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $195 · 2023: $148 · 2024: $162 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661 · Education: $27.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.06 |
| Education | $27.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185.50 | 2021-2022 | |
| Alkermes, INC. | $175.90 | 2022-2025 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $153.65 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $152.86 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $120.65 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $120.52 | 2021 | |
| Lundbeck LLC | $119.67 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $62.80 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $50.28 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Gachuma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.